Prospera Financial Services Inc Has $17.88 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Prospera Financial Services Inc lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 110,265 shares of the company's stock after purchasing an additional 16,428 shares during the period. Prospera Financial Services Inc's holdings in Johnson & Johnson were worth $17,881,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Meridian Financial Partners LLC acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $1,626,000. Meridian Investment Counsel Inc. boosted its holdings in Johnson & Johnson by 19.6% during the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares in the last quarter. Sheaff Brock Investment Advisors LLC boosted its holdings in Johnson & Johnson by 137.2% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 43,568 shares of the company's stock valued at $7,061,000 after purchasing an additional 25,203 shares in the last quarter. Lmcg Investments LLC boosted its holdings in Johnson & Johnson by 32.7% during the third quarter. Lmcg Investments LLC now owns 87,162 shares of the company's stock valued at $14,125,000 after purchasing an additional 21,471 shares in the last quarter. Finally, WealthPlan Investment Management LLC boosted its holdings in shares of Johnson & Johnson by 7.3% in the 3rd quarter. WealthPlan Investment Management LLC now owns 61,691 shares of the company's stock worth $9,998,000 after acquiring an additional 4,174 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 1.3 %

Shares of Johnson & Johnson stock traded down $2.07 during trading hours on Tuesday, reaching $152.70. 2,763,136 shares of the company's stock were exchanged, compared to its average volume of 7,000,485. The company has a 50 day moving average of $161.11 and a two-hundred day moving average of $156.16. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $367.64 billion, a P/E ratio of 22.11, a P/E/G ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the business posted $2.66 EPS. Johnson & Johnson's revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.25%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday. They issued an "outperform" rating and a $190.00 target price on the stock. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Guggenheim boosted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and dropped their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $175.94.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company's stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.